Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Muselaers CH, Stillebroer AB, Desar IM, Boers-Sonderen MJ, van Herpen CM, de Weijert MC, Langenhuijsen JF, Oosterwijk E, Leenders WP, Boerman OC, Mulders PF, Oyen WJ. Muselaers CH, et al. Among authors: van herpen cm. J Nucl Med. 2014 Feb;55(2):242-7. doi: 10.2967/jnumed.113.131110. Epub 2014 Jan 6. J Nucl Med. 2014. PMID: 24396030 Free article. Clinical Trial.
Current treatment of renal cell carcinoma.
De Mulder PH, van Herpen CM, Mulders PA. De Mulder PH, et al. Among authors: van herpen cm. Ann Oncol. 2004;15 Suppl 4:iv319-28. doi: 10.1093/annonc/mdh946. Ann Oncol. 2004. PMID: 15477330 Free article. Review. No abstract available.
Pharmacokinetics of sunitinib in an obese patient with a GIST.
Desar IM, Burger DM, Van Hoesel QG, Beijnen JH, Van Herpen CM, Van der Graaf WT. Desar IM, et al. Among authors: van hoesel qg, van der graaf wt, van herpen cm. Ann Oncol. 2009 Mar;20(3):599-600. doi: 10.1093/annonc/mdn779. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153120 Free article. No abstract available.
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM. Desar IM, et al. Among authors: van spronsen dj, van der graaf wt, van herpen cm. Acta Oncol. 2009;48(6):927-31. doi: 10.1080/02841860902974167. Acta Oncol. 2009. PMID: 19452305 No abstract available.
Time to target evaluation criteria of targeted therapies.
van Herpen CM, van der Graaf WT, Oyen WJ. van Herpen CM, et al. Among authors: van der graaf wt. Nucl Med Commun. 2009 Jul;30(7):487-9. doi: 10.1097/MNM.0b013e3283294d32. Nucl Med Commun. 2009. PMID: 19512845 No abstract available.
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM. van Laarhoven HW, et al. Among authors: van asten jj, van herpen cm. Clin Cancer Res. 2010 Feb 15;16(4):1315-23. doi: 10.1158/1078-0432.CCR-09-1621. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145168 Free article. Clinical Trial.
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. Banerji U, et al. Among authors: van herpen cm. Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179232 Free article. Clinical Trial.
251 results